These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2013210

  • 21. In vitro activity of BMY-28100, a new oral cephalosporin.
    Eliopoulos GM, Reiszner E, Wennersten C, Moellering RC.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):653-6. PubMed ID: 3496846
    [Abstract] [Full Text] [Related]

  • 22. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
    Neu HC, Chin NX, Labthavikul P.
    Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207
    [Abstract] [Full Text] [Related]

  • 23. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
    Jones RN.
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S77-83. PubMed ID: 7567314
    [Abstract] [Full Text] [Related]

  • 24. In-vitro activity and beta-lactamase stability of LY163892.
    Cao C, Chin NX, Neu HC.
    J Antimicrob Chemother; 1988 Aug; 22(2):155-65. PubMed ID: 3263352
    [Abstract] [Full Text] [Related]

  • 25. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.
    Neu HC.
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S88-92. PubMed ID: 7567316
    [Abstract] [Full Text] [Related]

  • 26. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
    Westblom TU, Gudipati S, Midkiff BR.
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):691-3. PubMed ID: 2226500
    [Abstract] [Full Text] [Related]

  • 27. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
    [Abstract] [Full Text] [Related]

  • 28. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R, Andrews JM, Ashby JP, Thornber D.
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482.
    Chin NX, Gu JW, Neu HC.
    Diagn Microbiol Infect Dis; 1991 Apr; 14(1):79-83. PubMed ID: 2013213
    [Abstract] [Full Text] [Related]

  • 30. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
    Pichichero ME, Doern GV, Kuti JL, Nicolau DP.
    Paediatr Drugs; 2008 Apr; 10(6):391-7. PubMed ID: 18998749
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.
    Jones RN, Barry AL.
    Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):802-7. PubMed ID: 3145869
    [Abstract] [Full Text] [Related]

  • 34. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
    Bauernfeind A, Jungwirth R, Eberlein E, Klesel N, Adam F, Isert D, Limbert M, Markus A, Schrinner E, Seibert G.
    J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
    [Abstract] [Full Text] [Related]

  • 35. [In vitro effect of cefixime against Haemophilus influenzae].
    Dabernat H, Delmas C.
    Presse Med; 1989 Oct 11; 18(32):1551-2. PubMed ID: 2530529
    [Abstract] [Full Text] [Related]

  • 36. In-vitro activity and beta-lactamase stability of SR 44337, a new long acting cephalosporin.
    Cooper MA, Andrews JM, Baldwin DR, Thornber D, Wise R.
    J Antimicrob Chemother; 1991 Aug 11; 28(2):229-37. PubMed ID: 1778854
    [Abstract] [Full Text] [Related]

  • 37. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
    Briggs BM, Jones RN, Erwin ME, Barrett MS, Johnson DM.
    Diagn Microbiol Infect Dis; 1991 Aug 11; 14(5):425-34. PubMed ID: 1797457
    [Abstract] [Full Text] [Related]

  • 38. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates].
    Ergova R, K'oleian E, Kharalambieva Ia, Mitov I, Docheva Iu.
    Vutr Boles; 2000 Aug 11; 32(1):13-7. PubMed ID: 11195191
    [Abstract] [Full Text] [Related]

  • 39. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA, Trujillano-Martín I, García-Sánchez JE.
    Drugs Exp Clin Res; 1993 Aug 11; 19(2):51-8. PubMed ID: 8223142
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.